Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03900104
Other study ID # CEIN
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2019
Est. completion date January 15, 2020

Study information

Verified date February 2020
Source Kocaeli University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators think that trans-cervical endometrial tracer injection will cause more paraaortic sentinel lymph node detection. Also, this application is easy, cost-effective and safer than hysteroscopic method. Transtubal tumor spearing will not occur with this method.


Description:

Endometrial tracer injection will be performed by cervical or transcervical endometrial methods. Pelvic and para-aortic sentinel lymph node detection capacity will be assessed in this study.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date January 15, 2020
Est. primary completion date January 1, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Endometrial Cancer Patients

- Suitable patients for surgical staging

Exclusion Criteria:

- Patients who cannot undergo cervical or transcervical endometrial injection

- Pathology did not confirm endometrial cancer

- Sarcoma of the uterine corpus

- If a 90-day follow-up was not feasible

Study Design


Intervention

Procedure:
Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles
Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
Cervical injection of technetium 99 m-labeled human albumin colloid particles
Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.

Locations

Country Name City State
Turkey Kocaeli University Kocaeli

Sponsors (1)

Lead Sponsor Collaborator
Kocaeli University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Niikura H, Kaiho-Sakuma M, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Takano T, Watanabe M, Ito K, Yaegashi N. Tracer injection sites and combinations for sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol. 2013 Nov;131(2):299-303. doi: 10.1016/j.ygyno.2013.08.018. Epub 2013 Aug 27. — View Citation

Solima E, Martinelli F, Ditto A, Maccauro M, Carcangiu M, Mariani L, Kusamura S, Fontanelli R, Grijuela B, Raspagliesi F. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. Gynecol Oncol. 2012 Sep;126(3):419-23. doi: 10.1016/j.ygyno.2012.05.025. Epub 2012 May 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Detected pelvic and paraaortic sentinel lymph node numbers Detected pelvic and paraaortic sentinel lymph node numbers in pathological examination (Ultrastaging) Postoperative 30 days
Secondary Numbers adverse events Number of adverse events associated with the surgery Postoperative 90 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06463028 - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02549989 - Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Phase 2